Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
The value of personalised medicines for healthcare systems in Europe

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 331

Anthony Barron - European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium

Anthony Barron speaks to ecancer at the WIN 2019 Symposium in Paris about the benefits of personalised treatments to patients, healthcare systems and society.

He explains the main benefits of this type of targeted treatment which include decreased hospitalisation costs, increased overall survival and reduced side effects.

Barron also mentions strategic and organisational barriers that still remain, including screening strategies and access to diagnostic technologies.

He also gives examples of some countries that have successfully implemented genomic strategies and national cancer plans. However, funding still remains to be the biggest hurdle in implementing an effective and accessible care strategy.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation